Shuttle Pharmaceuticals Holdings Inc (SHPH) - News Archive

Shuttle Pharmaceuticals Approaches Milestone in Phase 2 Clinical Trial for Ropidoxuridine in Glioblastoma Treatment Shuttle Pharmaceuticals Holdings, Inc. a pioneering player in the specialty pharmaceutical sector, has...

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a company dedicated to enhancing the care and outcomes of cancer patients undergoing radiation therapy, has announced a significant milestone in the development of...

Shuttle Pharmaceuticals: A New Alliance in Cancer Research Amidst Market Challenges In a significant development for both Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) and the broader field of oncology, the comp...

: Shuttle Pharmaceuticals Holdings, Inc. has announced the expansion of its Phase 2 clinical trial evaluating the efficacy of Ropidoxuridine for patients with glioblastoma. With patient enrollment now active at the UVA...

In a recent corporate update, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) revealed a challenging financial landscape as it navigates the complexities of the oncology market. The Gaithersburg, Maryland-based co...

On October 29, 2024, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a Maryland-based specialty pharmaceutical company dedicated to enhancing outcomes for cancer patients undergoing radiation therapy, announced t...

Shuttle Pharmaceuticals Advances Strategic Goals through Debt Payoff and New Public OfferingIn a notable demonstration of fiscal responsibility and strategic growth, Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH)...

Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma GAITHERSBURG, Md. Sept. 16, 2024 Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a p...

Advancements in Glioblastoma Treatment: Shuttle Pharmaceuticals Phase 2 Trial of Ropidoxuridine By A. B. Cumberbatch, Esq. CSIMarket.com , August 14, 2024. In the halcyon days of yore, the pursuit of scientific advancem...